The 36 rating InvestorsObserver gives to Halozyme Therapeutics, Inc. (HALO) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 48 percent of stocks in the Biotechnology industry, HALO’s 36 overall rating means the stock scores better than 36 percent of all stocks.
What do These Ratings Mean?
Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.
These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.
What's Happening With Halozyme Therapeutics, Inc. Stock Today?
Halozyme Therapeutics, Inc. (HALO) stock is down -2.79% while the S&P 500 is up 1.2% as of 12:09 PM on Thursday, May 13. HALO is lower by -$1.19 from the previous closing price of $42.48 on volume of 586,454 shares. Over the past year the S&P 500 has gained 45.81% while HALO is up 71.09%. HALO earned $1.13 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 36.51.
Click Here to get the full Stock Score Report on Halozyme Therapeutics, Inc. (HALO) Stock.
